glp-1 deal Medicare Drug Coverage oat beta glucan GLP-1 Updates for Employers: Demand,

While Im excited that patients may soon have more options, enthusiasm should not blind us to the risks

2015;308(8):F878F887

GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors GLP-1 receptor agonists, sodium glucose co-transporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors reduce the risk of MACE compared to placebo

Many states require this option for fully insured plans

however, no significant differences in eGFR decline were identified in any of the treatment groups [44]

These medications are transforming the treatment landscape, dramatically improving the amount of weight loss achievable through medication alone or in combination with lifestyle interventions, shared Miranda Stiewig-Rapp, assistant professor of endocrinology at UC Davis Health